Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides Or Sezary Syndrome

Trial Profile

Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides Or Sezary Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Feb 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018 as reported by ClinicalTrials.gov.
    • 23 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 19 Feb 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top